A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies

Hélène Sicard; Cécile Bonnafous; Ariane Morel; Martine Bagot; Armand Bensussan; Anne Marie-Cardine

doi:10.1080/2162402X.2015.1022306

A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies

Oncoimmunology. 2015 Jun 1;4(9):e1022306. doi: 10.1080/2162402X.2015.1022306. eCollection 2015 Sep.

Authors

Hélène Sicard¹, Cécile Bonnafous¹, Ariane Morel¹, Martine Bagot², Armand Bensussan², Anne Marie-Cardine²

Affiliations

¹ Innate Pharma R&D ; Marseille, France.
² INSERM U976; Hôpital Saint Louis; Pavillon Bazin ; Paris, France.

Abstract

Cutaneous T-cell lymphomas (CTCLs) represent a group of rarely occurring and clinically and pathologically heterogeneous diseases that are considered incurable at advanced stages. Current treatments provide limited clinical benefit and are thus largely amenable to improvement. An antibody-based CTCL-specific immunotherapy targeting the KIR3DL2 receptor expressed by the tumor cells in CTCL is currently under development and has shown encouraging results in pre-clinical studies.

Keywords: Antibody; CTCL; KIR3DL2; immunotherapy; non-clinical studies.